Global Synthetic Biology Market, By Tool (Oligonucleotides and Synthetic DNA, Enzymes, Cloning Technology Kits, Synthetic Cells, Chassis Organisms, Xeno-Nucleic Acids), Technology (Gene Synthesis, Genome Engineering, Sequencing, Bioinformatics, Cloning, Site-Directed Mutagenesis, Measurement and Modeling, Microfluids, Nanotechnology), Application (Medical Applications, Industrial Applications, Food and Agriculture, Environmental Applications), Products (Synthetic DNA, Synthetic Oligos, Synthetic Genes, Software Tools, Chassis Organisms, Synthetic Clones, Synthetic Cells) – Industry Trends and Forecast to 2029
Market Analysis and Size
Synthetic biology is an environmentally benign technology that has gained appeal for hazardous clean-up projects including synthetic microbes to digest refractory substances such as dioxins, insecticides, and even radioactive materials. Synthetic biology aids in the stabilisation of price growth in the medical industry, which drives up demand for this market. DNA synthesis technology and clustered regularly interspaced short palindromic repeats approaches have helped to lower the incidence of chronic diseases like cancer and diabetes. Biomedical, pharmaceutical, agricultural, biofuel, and chemical industries are all key users of this technology. Farmers can grow more crops on less area with synthetic biology, and it delivers more accuracy and perfection than prior gene technologies.
Data Bridge Market Research analyses that the synthetic biology market which was USD 9.5 billion in 2021, would rocket up to USD 48.81 billion by 2029, and is expected to undergo a CAGR of 22.70% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Tool (Oligonucleotides and Synthetic DNA, Enzymes, Cloning Technology Kits, Synthetic Cells, Chassis Organisms, Xeno-Nucleic Acids), Technology (Gene Synthesis, Genome Engineering, Sequencing, Bioinformatics, Cloning, Site-Directed Mutagenesis, Measurement and Modeling, Microfluids, Nanotechnology), Application (Medical Applications, Industrial Applications, Food and Agriculture, Environmental Applications), Products (Synthetic DNA, Synthetic Oligos, Synthetic Genes, Software Tools, Chassis Organisms, Synthetic Clones, Synthetic Cells)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Thermo Fisher Scientific Inc. (U.S), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S), Novozymes (Denmark), Ginkgo Bioworks (U.S), Amyris (U.S), Precigen Inc. (U.S), GenScript (China), Twist Bioscience (U.S), Synthetic Genomics (U.S), Codexis Inc. (U.S), Synthego (U.S), Creative Enzymes (U.S), Eurofins Scientific (Luxembourg), Cyrus Biotechnology Inc. (U.S), ATUM (U.S), TeselaGen (U.S), Arzeda (U.S), Integrated DNA Technologies Inc. (U.S), New England Biolabs (U.S)
Synthetic biology combines engineering and science to create unique biological systems with practical applications. Synthetic biology is the process of creating new biological units such as cells, enzymes, and genetic circuits and modifying existing biological systems. Synthetic biology's primary goal is to create new biological components that do not exist in nature, such as advanced biofuels, renewable chemicals, and bio goods. Synthetic biology discovers standardised genomic units that can be utilised to quickly synthesize and assemble small genomic parts into integrated large systems to tackle specific biological difficulties for the development of biological systems.
Synthetic Biology Market Dynamics
- Increase in synthetic drugs and vaccines
The market is predicted to expand as demand for protein therapies and personalised medicine grows and research into synthetic pharmaceuticals and vaccines. Other factors such as increased synthetic biology application, increased synthetic biology investment, lower DNA sequencing and synthesising costs, and increased R&D expenditure and activities are likely to accelerate synthetic biology market expansion during the forecast period of 2022 to 2029.
- Increased research and development funding
R&D spending in the life sciences industry climbed by 22% from 2018 to 2019, according to a Business Wire report published in September 2020. Pharmaceutical companies have received more funds for research and development in order to discover new therapies. The government has made steps to fund various pharmaceutical and biotech enterprises in order to advance pharmaceutically and boost international competitiveness. As a result, R&D spending and funding have steadily rised throughout the years. Pharmaceutical and biotechnology businesses devote significant resources to research in order to create game-changing compounds that will meet the expanding demands of the healthcare industry and tackle emerging ailments. Pharmaceutical research and development accounts for more than 80% of all R&D spending in the life sciences industry.
- Improving diagnosis and better treatment
Synthetic biology is used in the healthcare industry because it can help improve diagnostics and offer better treatment options for a variety of diseases by targeting only the disease site and creating no side effects. In addition, the use of genetically designed viruses to fix damaged genes in patients with inherited disorders such as epidermolysis bullosa or severe combined immune deficiency (SCID) has increased significantly. Aside from that, technologies for executing synthetic biology are becoming more accessible, and internet usage has facilitated free interchange of ideas and information, encouraging market expansion. Furthermore, the market is being influenced positively by significant expansion in the healthcare sector and an increase in the number of synthetic biology research units around the world.
- Demand for fuel alternatives
Biofuels are becoming increasingly important as fuel use rises and concerns about energy security develop. Annually, nearly 150 billion tonnes of biomass are produced worldwide. Biofuels are currently made from edible commodities such as maize, sugarcane, and vegetable oil. As a result, synthetic biology techniques are becoming more widely used in renewable energy development.
- Ethical and biosafety concerns
The purposeful or unintentional release of synthetic organisms into the environment during research and other purposes is the primary biosafety risk in synthetic biology. When synthetic microorganisms are released into the environment, they might mutate or interact with existing organisms, potentially causing crossbreeding and bio errors. These repercussions may pose a hazard to natural creatures' ecosystems. Additionally, the emergence of antibiotic-resistant superbugs is a huge biosecurity risk. In recent years, the European Union (EU) has supported a number of studies into the environmental impact of genetically altered bacteria released for plant growth or bioremediation. These factors may limit the market's growth in the following years.
This synthetic biology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the synthetic biology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Synthetic Biology Market
Pharmaceutical and biopharmaceutical businesses and synthetic biology market players have stepped up to help with global research efforts by providing synthetic biology for producing test kits, therapies, and vaccinations to combat coronavirus infection. A report from the European Parliament highlights synthetic biology as one of the developing technologies. It has the ability to combat the COVID-19 pandemic. The US National Institute of Health has also suggested synthetic biology as a technique to accelerate vaccine development. By employing their engineering methodologies founded on a range of data, synthetic biology technologies have the potential to alter the research and manufacture of vaccines, medicines, and diagnostics (genomic sequences, sequence annotations, enzyme properties, metabolic models, lab protocols, algorithms, and scientific knowledge). Vaccine technologies based on DNA and mRNA, for example, can make vaccine development and manufacture easier. These vaccines are made up of synthetic nucleotide strands that cause proteins to develop in the individual's own cells, triggering an immunological response. As a result of the availability of viral sequencing data, vaccination candidates can be developed quickly. This has allowed companies like Moderna and Inovio to proceed quickly into clinical development.
- In January 2021, Frontia GlutenEx was developed by Novozymes. It would assist wheat processors in improving gluten protein recovery while reducing energy use.
- In February 2021, Merck collaborated with BioNTech (Germany) to provide lipids for the Pfizer-BioNTech COVID-19 vaccine (BNT162b2).
- In January 2021, Merck bought AmpTec (Germany). The company expanded its product portfolio by developing and manufacturing mRNA for use in vaccinations, therapies, and diagnostics as a result of this purchase.
Global Synthetic Biology Market Scope
The synthetic biology market is segmented on the basis of tool, technology and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Oligonucleotides and Synthetic DNA
- Cloning Technologies Kits
- Synthetic Cells
- Chassis Organisms
- Xeno-nucleic Acids
- Gene Synthesis
- Genome Engineering
- Site-directed Mutagenesis
- Measurement and Modeling
- Medical Application
- Drug Discovery and Therapeutics
- Cancer Detection and Diagnostics
- Other Drug Discovery and Therapeutic Applications
- Artificial Tissue and Tissue Regeneration
- Stem Cell Regulation
- Other Tissue and Tissue Regeneration Applications
- Industrial Applications
- Biofuel and Renewable Energy
- Biomaterials and Green Chemicals
- Industrial Enzymes, by Application
- Textile Industry
- Paper Industry
- Consumer Care Industry
- Skin Care and Cosmetics
- Other Consumer Care Products
- Other Industries
- Food and Agriculture
- Environmental Applications
Synthetic biology Market Regional Analysis/Insights
The synthetic biology market is analysed and market size insights and trends are provided by country, tool, technology and application as referenced above.
The countries covered in the synthetic biology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominating the synthetic biology market, due to various factors such as the increase in the number of well-established synthetic biology companies and research institutes in the US and Canada.
Asia-Pacific is expected to grow the synthetic biology market in the forecast period of 2022 to 2029 due to the growing number of pharmaceutical and biopharmaceutical companies and increasing healthcare and life science facilities which is expected to improve the synthetic biology market in forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Synthetic Biology Market Share Analysis
The synthetic biology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to synthetic biology market.
Some of the major players operating in the synthetic biology market are:
- Thermo Fisher Scientific Inc. (U.S)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (U.S)
- Novozymes (Denmark)
- Ginkgo Bioworks (U.S)
- Amyris (U.S)
- Precigen Inc. (U.S)
- GenScript (China)
- Twist Bioscience (U.S)
- Synthetic Genomics (U.S)
- Codexis Inc. (U.S)
- Synthego (U.S)
- Creative Enzymes (U.S)
- Eurofins Scientific (Luxembourg)
- Cyrus Biotechnology Inc. (U.S)
- ATUM (U.S)
- TeselaGen (U.S)
- Arzeda (U.S)
- Integrated DNA Technologies Inc. (U.S)
- New England Biolabs (U.S)